HK1049657A1 - 用於製備具有多種治療特性的三取代的咪唑化合物的亞胺中間體 - Google Patents

用於製備具有多種治療特性的三取代的咪唑化合物的亞胺中間體

Info

Publication number
HK1049657A1
HK1049657A1 HK03100345.9A HK03100345A HK1049657A1 HK 1049657 A1 HK1049657 A1 HK 1049657A1 HK 03100345 A HK03100345 A HK 03100345A HK 1049657 A1 HK1049657 A1 HK 1049657A1
Authority
HK
Hong Kong
Prior art keywords
preparation
imidazole compounds
therapeutic properties
multiple therapeutic
imine intermediates
Prior art date
Application number
HK03100345.9A
Other languages
English (en)
Inventor
Leroy Adams Jerry
William Sheldrake Peter
Francis Gallagher Timothy
Shanker Garigipati Ravi
Elliot Bender Paul
Charles Boehm Jeffrey
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HK1049657A1 publication Critical patent/HK1049657A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
HK03100345.9A 1993-07-16 1998-12-16 用於製備具有多種治療特性的三取代的咪唑化合物的亞胺中間體 HK1049657A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9273393A 1993-07-16 1993-07-16

Publications (1)

Publication Number Publication Date
HK1049657A1 true HK1049657A1 (zh) 2003-05-23

Family

ID=22234840

Family Applications (4)

Application Number Title Priority Date Filing Date
HK03100345.9A HK1049657A1 (zh) 1993-07-16 1998-12-16 用於製備具有多種治療特性的三取代的咪唑化合物的亞胺中間體
HK98113635A HK1012392A1 (en) 1993-07-16 1998-12-16 Tri-substituted imidazoles having multiple therapeutic properties
HK03100350.1A HK1049659A1 (zh) 1993-07-16 1998-12-16 具有多種治療特性的三-取代咪唑化合物製備用異氰化物的中間體
HK03100349.5A HK1049658A1 (zh) 1993-07-16 1998-12-16 具有多種治療特性的三-取代咪唑化合物製備用甲酰胺中間體

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK98113635A HK1012392A1 (en) 1993-07-16 1998-12-16 Tri-substituted imidazoles having multiple therapeutic properties
HK03100350.1A HK1049659A1 (zh) 1993-07-16 1998-12-16 具有多種治療特性的三-取代咪唑化合物製備用異氰化物的中間體
HK03100349.5A HK1049658A1 (zh) 1993-07-16 1998-12-16 具有多種治療特性的三-取代咪唑化合物製備用甲酰胺中間體

Country Status (31)

Country Link
EP (5) EP0708768B1 (zh)
JP (4) JPH09500137A (zh)
CN (2) CN1050126C (zh)
AP (1) AP484A (zh)
AT (2) ATE236896T1 (zh)
AU (1) AU694130C (zh)
BR (2) BR9407079A (zh)
CA (1) CA2167311A1 (zh)
CZ (1) CZ11996A3 (zh)
DE (2) DE69434316T2 (zh)
DK (1) DK0708768T3 (zh)
DZ (1) DZ1798A1 (zh)
ES (2) ES2197167T3 (zh)
FI (1) FI960177A0 (zh)
HK (4) HK1049657A1 (zh)
HU (1) HUT75313A (zh)
IL (2) IL110296A (zh)
MA (1) MA23270A1 (zh)
MY (1) MY116478A (zh)
NO (4) NO316881B1 (zh)
NZ (2) NZ329994A (zh)
PL (4) PL181705B1 (zh)
PT (1) PT708768E (zh)
RU (1) RU2140918C1 (zh)
SG (1) SG52368A1 (zh)
SI (1) SI0708768T1 (zh)
SK (1) SK282342B6 (zh)
TW (1) TW330934B (zh)
UA (1) UA63875C2 (zh)
WO (1) WO1995002591A1 (zh)
ZA (1) ZA945193B (zh)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857751A (en) * 1971-11-15 1974-12-31 Tufdura Ltd Composite sheet capable of withstanding impingement by particulate materials
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
GB9500580D0 (en) * 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
MX9705296A (es) * 1995-01-12 1997-10-31 Smithkline Beecham Corp Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
NZ327044A (en) * 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001508395A (ja) * 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション 新規シクロアルキル置換イミダゾール
US6372741B1 (en) * 1996-03-08 2002-04-16 Smithkline Beecham Corporation Use of CSAID™ compounds as inhibitors of angiogenesis
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
WO1997047618A1 (en) * 1996-06-10 1997-12-18 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
EP0994870A4 (en) 1997-06-19 2002-10-23 Smithkline Beecham NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
JP3337992B2 (ja) * 1997-11-04 2002-10-28 ファイザー製薬株式会社 ５−置換ピコリン酸化合物及びその製造方法
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
GB9809869D0 (en) * 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
TR200003472T2 (tr) 1998-05-22 2001-09-21 Smithkline Beecham Corporation Yeni 2-alkil ikameli imidazol bileşikler
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
AU4273099A (en) 1998-06-24 2000-01-10 Medical Research Council Polypeptides, polynucleotides and uses thereof
WO2000001688A1 (fr) * 1998-07-02 2000-01-13 Sankyo Company, Limited Composes heteroaryle a cinq elements
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
EP1112070B1 (en) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
AU1909200A (en) 1998-11-04 2000-05-22 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
DE60020595T2 (de) 1999-11-23 2006-03-16 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6627647B1 (en) * 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
FR2823751B1 (fr) * 2001-04-24 2003-05-23 Oreal Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
FR2823747B1 (fr) * 2001-04-24 2003-05-23 Oreal Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
CN101597262A (zh) * 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
DE60334016D1 (de) 2002-11-05 2010-10-14 Glaxo Group Ltd Antibakterielle mittel
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
CA2599879C (en) * 2005-03-11 2013-07-02 Zenyaku Kogyo Kabushikikaisha Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
TWI517850B (zh) 2009-09-30 2016-01-21 Ｖｔｖ治療有限責任公司 經取代之咪唑衍生物及其使用方法
EP2493876B1 (en) * 2009-10-28 2014-02-12 Pfizer Inc Imidazole derivatives as casein kinase inhibitors
CN104387301B (zh) * 2014-11-11 2016-05-04 常州大学 一种2-氟-4-甲基苯磺酰甲基异腈的合成方法
CN113350353A (zh) 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
AU2018262108A1 (en) * 2017-05-03 2019-11-21 The University Of Melbourne Compounds for the treatment of respiratory diseases
CN114112812A (zh) * 2021-10-29 2022-03-01 华北电力大学 相变颗粒测试装置、固-液相变机理可视化实验台及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
WO1992010190A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
EP0563286A4 (en) * 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions

Also Published As

Publication number Publication date
NO20010839D0 (no) 2001-02-19
PT708768E (pt) 2003-08-29
EP0708768A1 (en) 1996-05-01
TW330934B (en) 1998-05-01
ZA945193B (en) 1995-04-20
PL181721B1 (en) 2001-09-28
NO10838A (no) 1996-01-15
MA23270A1 (fr) 1995-04-01
HK1049658A1 (zh) 2003-05-23
DK0708768T3 (da) 2003-08-04
EP1227091A3 (en) 2002-08-07
HU9503855D0 (en) 1996-02-28
CN1050126C (zh) 2000-03-08
NZ329994A (en) 1999-07-29
EP1227091A2 (en) 2002-07-31
RU2140918C1 (ru) 1999-11-10
PL181723B1 (pl) 2001-09-28
JPH09500137A (ja) 1997-01-07
ATE236896T1 (de) 2003-04-15
IL124318A0 (en) 1998-12-06
JP2004149541A (ja) 2004-05-27
SK4796A3 (en) 1997-01-08
CA2167311A1 (en) 1995-01-26
NO20010837D0 (no) 2001-02-19
SK282342B6 (sk) 2002-01-07
EP0708768A4 (en) 1996-08-21
WO1995002591A1 (en) 1995-01-26
HK1049659A1 (zh) 2003-05-23
NO960173D0 (no) 1996-01-15
EP1291346A1 (en) 2003-03-12
EP0708768B1 (en) 2003-04-09
EP1227092A2 (en) 2002-07-31
MY116478A (en) 2004-02-28
DE69434316T2 (de) 2006-03-09
UA63875C2 (en) 2004-02-16
HUT75313A (en) 1997-05-28
CN1218801A (zh) 1999-06-09
CZ11996A3 (en) 1996-10-16
ES2237650T3 (es) 2005-08-01
DE69434316D1 (de) 2005-04-28
AU694130C (en) 2002-12-05
CN1129447A (zh) 1996-08-21
SG52368A1 (en) 1998-09-28
NO960173L (no) 1996-01-15
NZ269457A (en) 1998-08-26
AU694130B2 (en) 1998-07-16
NO20010838D0 (no) 2001-02-19
SI0708768T1 (en) 2003-10-31
FI960177A (fi) 1996-01-15
IL110296A (en) 1999-12-31
BR1100546A (pt) 2004-08-31
AU7335494A (en) 1995-02-13
EP1291346B1 (en) 2005-03-23
AP484A (en) 1996-04-23
NO316881B1 (no) 2004-06-14
IL110296A0 (en) 1994-10-21
EP1227092A3 (en) 2002-08-07
NO10837A (no) 1996-01-15
JP2004099622A (ja) 2004-04-02
DZ1798A1 (fr) 2002-02-17
EP1229035A1 (en) 2002-08-07
DE69432463T2 (de) 2004-02-12
ATE291576T1 (de) 2005-04-15
AP9400654A0 (en) 1994-07-31
DE69432463D1 (de) 2003-05-15
BR9407079A (pt) 1996-08-27
AU705568B2 (en) 1999-05-27
PL181705B1 (pl) 2001-09-28
JP2004083600A (ja) 2004-03-18
PL181694B1 (pl) 2001-09-28
AU7185098A (en) 1998-08-27
HK1012392A1 (en) 1999-07-30
PL312614A1 (en) 1996-04-29
FI960177A0 (fi) 1996-01-15
NO10839A (no) 1996-01-15
ES2197167T3 (es) 2004-01-01

Similar Documents

Publication Publication Date Title
HK1049657A1 (zh) 用於製備具有多種治療特性的三取代的咪唑化合物的亞胺中間體
AU3428393A (en) Use of polyamines as ionic-channel regulating agents
ZA951107B (en) Substituted spiro compounds for the treatment of inflammation
AU6623894A (en) Therapeutic compounds
AU4293193A (en) Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
AU6092794A (en) Oxime-substituted therapeutic compounds
IL132532A (en) Intermediates for the preparation of substituted cephalosporins
ZA964010B (en) Use of pyrrole compounds as antifouling agents.
AU2964495A (en) Vicinal-substituted carbocyclic compounds as therapeutic agents
EP0584655A3 (en) 3-aryl-triazine-2,4-diones as herbicides
AU5095093A (en) Process for the preparation of tetrazoles
AU8463691A (en) Processes for the preparation of nitrogen-containing compounds
AU4712696A (en) The use of heterocyclic compounds
ZA968550B (en) Novel processes for the preparation of anti-malarial compounds.
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
AU5643594A (en) Process for the preparation of organochlorosilanes
AU5371694A (en) Use of the tarchonanthus camphoratus
GB9415313D0 (en) The preparation of organic compounds
HK1013293A1 (en) Process for the preparation of methylchlorosilane
AU3964093A (en) Novel use of nitroimidazoles
GB9304071D0 (en) Process for the preparation of nitriles
AU7866894A (en) The use of inositoltrisphosphate for the preparing of medicaments
GB2275267B (en) Preparation of dicyanobenzenes by ammoxidation
ZA956322B (en) The preparation of organic compounds
AU2671895A (en) Bisquinolines for the treatment of malaria